OV announces prolongation of option to buy back shares in OV SPV2 that holds TKI product from BigPharma

On November 16, 2017, Oncology Venture Sweden AB ("Oncology Venture") has agreed with one of the major investors in OV-SPV2 ApS to prolong the option to buy back shares in OV-SPV2 that holds the TKI product from Novartis. The option will be prolonged with six (6) months – until June 1st 2018. The major investor wishes to maintain an ownership of 15% in OV-SPV2 ApS.

Option agreement

Oncology Venture announced on the 23rd October that data on the TKI project from Novartis is expected to be published within 6-8 weeks. The major investor and Oncology Venture has agreed to prolong Oncology Venture’s option to buy back shares in OV-SPV2 ApS.

Previously the Oncology Ventures option was to acquire 50% of the shares for 5 million USD before 1st December 2017.

The option has been modified - now Oncology Venture can acquire 35% of the shares in OV-SPV2 for 3,5 million USD before 1st June 2018.

Oncology Venture currently owns 40% of OV-SPV2. If Oncology Venture exercises the option Oncology Venture will own 75% of OV-SPV2.

“We will very soon see if we can predict response to this major product and I’m very happy that our major investor continues to support the project and that we have got this agreement in place”, says Peter Buhl Jensen, MD, PhD and CEO of Oncology Venture. If our DRP technology can segment the patients benefitting to the TKI product it will be a game changer in this blockbuster type of products” Buhl Jensen further comments. 

TKI information: 

Comparable TKI products approved for the market has annual global sales of 700 – 1,100 million USD and Oncology Venture’s TKI product at hand has demonstrated same efficacy and safety in a direct comparison with one of these already market approved product in a clinical trial. If OV can demonstrate that the DRP® can find responders it will contact the FDA and ask for an “end of phase 2 meeting”.

For further information, please contact

Ulla Hald Buhl,
COO and Chief IR & Communications
Mobile: +45 2170 1049
or   Peter Buhl Jensen,
Mobile: +45 21 60 89 22
E-mail: pbj@oncologyventure.com 

This information is information that Oncology Venture Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 16th November 2017.

About Oncology Venture Sweden AB 

Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.

The current product portfolio: LiPlaCis for Breast Cancer, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma.

Oncology Venture has spun out two companies in Special Purpose Vehicles: 2X Oncology Inc. a US based company focusing on Precision medicine for women’s cancers with a pipeline of three promising phase 2 product candidates and Danish OV-SPV 2 will test and potentially develop an oral phase 2 Tyrosine Kinase inhibitor.


Documents & Links